Details of Disease

General Information of Disease (ID: DIS62JY3)

Disease Name	Irritant contact dermatitis
Synonyms	primary irritant dermatitis; irritant contact dermatitis
Disease Class	EK02: Irritant contact dermatitis
Definition	An inflammatory skin condition caused by direct contact between the skin and an irritating substance. It is typically manifested by erythema, mild edema, and scaling at the affected site.
Disease Hierarchy	DISQ3AU0: Contact dermatitis DIS62JY3: Irritant contact dermatitis
ICD Code	ICD-11 ICD-11: EK02 ICD-10 ICD-10: L24, L24.8 Expand ICD-11 'EK02 Expand ICD-10 'L24; 'L24.8
Disease Identifiers	MONDO ID MONDO_0006564 MESH ID D017453 UMLS CUI C0162823 MedGen ID 56513 SNOMED CT ID 110979008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ac-YVAD-cmk	DMA1RVN	Patented	Peptide	[1]
Ac-YVAD-FMK	DM7K256	Patented	Peptide	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CBR1	TTVG0SN	Limited	Therapeutic	[2]
IL4	TTLGTKB	Limited	Biomarker	[3]
------------------------------------------------------------------------------------

This Disease Is Related to 11 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
C2	OTHMF4YM	Strong	Biomarker	[4]
CCL24	OT9LGHV0	Strong	Biomarker	[5]
FLG	OTE9QDV6	Strong	Genetic Variation	[6]
HLA-DPA1	OT7OG7Y2	Strong	Biomarker	[4]
HLA-DPB1	OTW8JHU2	Strong	Biomarker	[4]
IER3	OTZJI5FZ	Strong	Biomarker	[4]
OR2B3	OTPVDG2N	Strong	Biomarker	[4]
PLCD1	OT6WFVXZ	Strong	Biomarker	[7]
TRIM10	OTEO4UCZ	Strong	Biomarker	[4]
TRIM31	OT7VW6RP	Strong	Biomarker	[4]
TRIM40	OTLKKKA5	Strong	Biomarker	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DOT(s)

References

1	Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59.
2	Tat-CBR1 inhibits inflammatory responses through the suppressions of NF-B and MAPK activation in macrophages and TPA-induced ear edema in mice.Toxicol Appl Pharmacol. 2015 Jul 15;286(2):124-34. doi: 10.1016/j.taap.2015.03.020. Epub 2015 Mar 25.
3	Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats.Skin Pharmacol Physiol. 2009;22(5):240-7. doi: 10.1159/000235551. Epub 2009 Aug 18.
4	Association of MHC region SNPs with irritant susceptibility in healthcare workers. J Immunotoxicol. 2016 Sep;13(5):738-44. doi: 10.3109/1547691X.2016.1173135. Epub 2016 Jun 3.
5	Pre-administration of PepFect6-microRNA-146a nanocomplexes inhibits inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis.J Control Release. 2016 Aug 10;235:195-204. doi: 10.1016/j.jconrel.2016.06.006. Epub 2016 Jun 3.
6	Impact of atopic dermatitis and loss-of-function mutations in the filaggrin gene on the development of occupational irritant contact dermatitis.Br J Dermatol. 2013 Feb;168(2):326-332. doi: 10.1111/bjd.12083.
7	Epidermal loss of phospholipase C1 attenuates irritant contact dermatitis.Biochem Biophys Res Commun. 2019 Apr 2;511(2):330-335. doi: 10.1016/j.bbrc.2019.02.046. Epub 2019 Feb 18.